Posted by Michael Wonder on 06 Oct 2022
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma
28 September 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of polatuzumab vedotin in the NHS in England.
Polatuzumab vedotin, when used in combination with rituximab, cyclophosphamide, doxorubicin hydrochloride and prednisolone, is not recommended for the treatment of adults with untreated diffuse large B-cell lymphoma.
